Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Common Equity: 2018-2025

Historic Common Equity for Bicycle Therapeutics (BCYC) over the last 8 years, with Sep 2025 value amounting to $618.5 million.

  • Bicycle Therapeutics' Common Equity fell 25.58% to $618.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $618.5 million, marking a year-over-year decrease of 25.58%. This contributed to the annual value of $793.1 million for FY2024, which is 113.80% up from last year.
  • Latest data reveals that Bicycle Therapeutics reported Common Equity of $618.5 million as of Q3 2025, which was down 7.54% from $668.9 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Common Equity ranged from a high of $873.8 million in Q2 2024 and a low of $142.1 million during Q2 2021.
  • For the 3-year period, Bicycle Therapeutics' Common Equity averaged around $557.4 million, with its median value being $618.5 million (2025).
  • Its Common Equity has fluctuated over the past 5 years, first dropped by 29.32% in 2023, then skyrocketed by 297.01% in 2024.
  • Quarterly analysis of 5 years shows Bicycle Therapeutics' Common Equity stood at $346.3 million in 2021, then fell by 21.80% to $270.8 million in 2022, then skyrocketed by 36.98% to $370.9 million in 2023, then soared by 113.80% to $793.1 million in 2024, then dropped by 25.58% to $618.5 million in 2025.
  • Its Common Equity was $618.5 million in Q3 2025, compared to $668.9 million in Q2 2025 and $740.3 million in Q1 2025.